Knockdown of Trio by CRISPR/Cas9 suppresses migration and invasion of cervical cancer cells

Hou, Chunying; Zhuang, Zirong; Deng, Xinchao; Xu, Yueqin; Zhang, Ping; Zhu, Lin

doi:10.3892/or.2017.6117

Cited by 13 publications

(12 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cervical cancer was reported as the third most common gynecological malignancy worldwide in 2012 (13). In China, the incidence of cervical cancer ranks first among malignant tumors in the female reproductive system (14), and >99% of patients with cervical cancer are infected with HPV (11,15,16).…”

Section: Discussionmentioning

confidence: 99%

A three-gene novel predictor for improving the prognosis of cervical cancer

Ding

Feng

2019

Oncol Lett

View full text Add to dashboard Cite

Cervical cancer is the most common gynecological malignancy, the third most common malignant tumor in women worldwide, and the most common malignant tumor among Chinese women. However, despite continuous improvement in medical treatment, the number of cervical cancer cases in China is on the increase annually, consistent with the general trend in global cervical cancer incidence. Therefore, it is particularly important to study the pathogenesis of cervical cancer at the genetic level in China. The aim of the present study was to use the TCGA database to identify potential genetic signatures that could predict the prognosis of patients with cervical cancer and provide evidence supporting clinical genetic intervention in cervical cancer. Primarily, an effective three-gene signature was found that predicts prognosis in patients with cervical cancer. This model can provide prima facie evidence for future assessment of patient risk and prognosis, but further testing is required to improve its accuracy. Our results also suggested that centromere protein M, methionine sulfoxide reductase B3 and Zic family member 2 could be promising biomarkers for the prognosis of cervical cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

A three-gene novel predictor for improving the prognosis of cervical cancer

Ding

Feng

2019

Oncol Lett

View full text Add to dashboard Cite

show abstract

“…As one of the fatal malignant neoplasms, the morbidity of cervical carcinoma remains has drastically increased worldwide. After cervical carcinoma cell diffuses to secondary tissues, cervical carcinoma becomes resistant to the conventional therapeutic methods and become an incurable disease 1,2. MicroRNAs, which are small non-coding RNAs, post-transcriptionally regulate the expressions of their downstream target genes 3.…”

Section: Introductionmentioning

confidence: 99%

<p>MiR-155-5p accelerates the metastasis of cervical cancer cell via targeting TP53INP1</p>

Li¹,

Tao

Guo³

et al. 2019

OTT

View full text Add to dashboard Cite

Background: The dysregulation of microRNAs has been implicated in the progression of different malignancies. Herein, we sought to identify the precise roles of miR-155-5p in the progression of cervical cancer. Materials and methods: The expressions of miR-155-5p in cervical carcinoma cells and clinical tissues were assessed using qRT-PCR analysis. The functions of miR-155-5p on the growth of cervical cancer cell were investigated using MTT and colony formation. The Transwell and wound closure assays were selected to explore the influence of miR-155-5p on the invasion and migration of cervical cancer cell. The effect of miR-155-5p on cervical carcinoma cell growth and metastasis in vivo was investigated using xenograft model and experimental lung metastasis model. Bioinformatics analysis and luciferase reporter assay were applied to identify that tumor protein p53-inducible nuclear protein 1 (TP53INP1) was the target of miR-155-5p. Results: MiR-155-5p was significantly upregulated in cervical cancer tissue than that in control normal tissue. Downexpression of miR-155-5p decreased the growth, migration as well as invasiveness abilities of cervical cancer cell in vitro whereas overregulation of miR-155-5p caused the opposite outcomes. In addition, the in vivo mice xenograft model suggested that downexpression of miR-155-5p restrained the progression of cervical cancer cell whereas overexpression of miR-155-5p caused opposite outcomes. Furthermore, we revealed that TP53INP1 was the target of miR-155-5p and the level of TP53INP1 was inversely associated with miR-155-5p level in cervical carcinoma. Furthermore, TP53INP1 knockdown mimicked the influence of miR-155-5p on cervical cancer proliferation, migration and invasion phenotypes. Finally, overexpression of TP53INP1 impaired the promote effect of miR-155-5p on cervical cancer cell and downregulation of TP53INP1 counteracted the suppressive impact of miR-155-5p on the aggressiveness of cervical cancer cell. Conclusion: Our study indicated that miR-155-5p regulated the development of cervical cancer cell by regulating the expression of TP53INP1.

show abstract

“…The pathogenic mechanism of HPV is mainly through the viral oncoproteins E6 and E7, where E6 protein binds to the host pro‐apoptotic tumor suppressor, p53, and E7 binds to the retinoblastoma tumor suppressor protein, retinoblastoma protein (pRb), eventually causing cell proliferation, deformation, and canceration . As CRISPR‐Cas9 can efficiently cut and knock out pathogenic genes, it brings new hope for cervical cancer treatment, and it has in recent years made great progress in cervical cancer treatment (summarized in Table ).…”

Section: Cervical Cancer and Crispr‐cas9mentioning

confidence: 99%

“…Knockout of SERPINB3 (the gene encoding SCCA1) in SW756 cells increases the sensitivity of cervical cancer cells to radiation . The RhoA‐/‐ROCK signaling pathway can be suppressed after knockout of the Trio gene by employing CRISPR‐Cas9 in the cervical cancer cell lines, CaSki and HeLa, thereby inhibiting the migration and metastasis of cervical cancer . In addition, CRISPR‐Cas9 has been developed for the detection and typing of HPV and can be used to screen high‐risk HPV infection in cervical cancer, and the general process as shown in the Figure .…”

Section: Cervical Cancer and Crispr‐cas9mentioning

confidence: 99%

Applications of CRISPR‐Cas9 in gynecological cancer research

et al. 2020

View full text Add to dashboard Cite

Gynecological cancers pose a significant threat to women's health worldwide, with cervical cancer, ovarian cancer, and endometrial cancer having high incidences.Current gynecological cancer treatment methods mainly include surgery, chemotherapy, radiotherapy, and chemoradiotherapy. The CRISPR-Cas9 gene editing technology as a new therapeutic method has shown tremendous effect in the treatment of other cancers, promoting research on its potential therapeutic effect in gynecological cancer. In this article, we reviewed the current research status of CRISPR-Cas9 technology in gynecological cancer, focusing on the importance of studying the mechanism of CRISPR-Cas9 in gynecological cancer treatment, thereby laying a foundation for further research on its clinical application. K E Y W O R D S cancer treatment, CRISPR-Cas9, gene editing, gynecological cancers 1 | INTRODUCTIONThe CRISPR sequence, a cluster of regularly spaced short palindromic repeats, is a special ordered repeating sequence found in the genome of Escherichia coli. The CRISPR-Cas9 system constitutes the acquired immune system of E. coli. 1 In 2012, scientists discovered that the CRISPR-Cas9 system can produce mature CRISPR RNA (crRNA) and trans-activating crRNA (tracrRNA), which form a composite structure and have a directional guidance function to guide Cas9 to specific DNA sequences, resulting in DNA double-strand breaks. 2 By 2013, scientists had successfully edited the genome of eukaryotic cells using the CRISPR-Cas9 system. [3][4][5] Since then, the CRISPR-Cas9 gene editing technology has dramatically impacted the field of life sciences and has become one of the most significant research areas at present. The working principle of the CRISPR-Cas9 system is to artificially design two kinds of RNA: crRNA and tracrRNA, and then transform them into a single guide RNA (sgRNA), thereby guiding Cas9 to cut DNA in a targeted manner, following which cells are able to delete the target DNA through homologous and non-homologous DNA damage repair mechanisms. 6 Compared with traditional gene editing tools, such as ZFN and TALEN, the CRISPR-Cas9 technology has the advantages of simple design, ability to target any DNA sequence in the cell and to target multiple targets simultaneously, higher cutting efficiency, and lower cost. 7 At present, the CRISPR-Cas9 gene editing technology has contributed to great advancements in the clinical treatment of diseases. Major breakthroughs have been achieved in treating hereditary diseases using this technology. [8][9][10] It was used to knock out the beta-globin gene, the pathogenic gene of β-hemoglobinopathy, and it also employed rAAV6, as a donor template, to effectively correct the disease-causing mutation of SCD through homologous recombination. 10 In addition, The CRISPR-Cas9 gene editing technology has been widely used treatment-related researches and in the establishment of disease model of many cancers, including pancreatic, lung, gastric, colon, kidney, liver, head and neck, and skin cancers. [11][12][13][14][15][16][...

show abstract

Knockdown of Trio by CRISPR/Cas9 suppresses migration and invasion of cervical cancer cells

Cited by 13 publications

References 37 publications

A three-gene novel predictor for improving the prognosis of cervical cancer

A three-gene novel predictor for improving the prognosis of cervical cancer

<p>MiR-155-5p accelerates the metastasis of cervical cancer cell via targeting TP53INP1</p>

Applications of CRISPR‐Cas9 in gynecological cancer research

Contact Info

Product

Resources

About